Scopolamine Transdermal

Active ingredient: Scopolamine

In short: Scopolamine transdermal system is indicated in adults for the prevention of: •nausea and vomiting associated with motion sickness. •post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery.

Forms & strengthsTransdermal system: a circular, flat, tan-colored transdermal system imprinted with “SCOP 1 mg/3 days” in a repeating pattern.
LabelPadagis Israel Pharmaceuticals Ltd
Label updatedNov 17, 2025

What is Scopolamine Transdermal used for?

Scopolamine transdermal system is indicated in adults for the prevention of:

•nausea and vomiting associated with motion sickness.

•post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery.

Scopolamine Transdermal dosage

•Each scopolamine transdermal system is formulated to deliver in vivo approximately 1 mg of scopolamine over 3 days.

•Only wear one transdermal system at any time.

•

Do not cut the transdermal system.

•Apply the transdermal system to the skin in the postauricular area (hairless area behind one ear).

•After the transdermal system is applied on the dry skin behind the ear, wash hands thoroughly with soap and water and dry hands .

•If the transdermal system becomes displaced, discard the transdermal system, and apply a new transdermal system on the hairless area behind the other ear.

•Once the transdermal system has been affixed, avoid touching or applying pressure to the transdermal system while it is being worn, since pressure exerted on it may cause scopolamine to ooze out at the edge.

•Upon removal, fold the used transdermal system in half with the sticky side together, and discard in household trash in a manner that prevents accidental contact or ingestion by children, pets or others.

•Wash the hands and application site with soap and water after transdermal system removal .

Motion Sickness

Apply one scopolamine transdermal system to the hairless area behind one ear at least 4 hours before the antiemetic effect is required – for use up to 3 days. If therapy is required for longer than 3 days, remove the first transdermal system and apply a new scopolamine transdermal system behind the other ear.

PONV

For surgeries other than cesarean section: Apply one scopolamine transdermal system the evening before scheduled surgery. Remove the transdermal system 24 hours following surgery.

How to take Scopolamine Transdermal — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Administration Instructions

Counsel patients on how to apply and remove the transdermal system :

•Only wear one transdermal system at any time.

•Do not cut the transdermal system.

•Apply the transdermal system to the skin in the postauricular (hairless area behind one ear) area.

•After the transdermal system is applied on the dry skin behind the ear, wash hands thoroughly with soap and water and dry hands.

•If the transdermal system becomes displaced, discard the transdermal system, and apply a new transdermal system on the hairless area behind the other ear.

•Once the transdermal system has been affixed, avoid touching or applying pressure to the transdermal system, since pressure exerted on it may cause scopolamine to ooze out at the edge.

•Upon removal, fold the used transdermal system in half with the sticky side together, and discard in household trash in a manner that prevents accidental contact or ingestion by children, pets or others.

•Wash the hands and application site with soap and water after transdermal system removal. …

Warnings & precautions

Do not take this medicine if: Scopolamine transdermal system is contraindicated in patients with:

•angle closure glaucoma .

•hypersensitivity to scopolamine or other belladonna alkaloids or to any ingredient or component in the formulation or delivery system. Reactions have included rash generalized and erythema .

The mydriatic effect of scopolamine may cause an increase in intraocular pressure resulting in acute angle closure glaucoma. Monitor intraocular pressure in patients with open angle glaucoma and adjust glaucoma therapy during scopolamine transdermal system use, as needed. Advise patients to immediately remove the transdermal system and contact their healthcare provider if they experience symptoms of acute angle closure glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema).

Psychiatric Adverse Reactions

Scopolamine has been reported to exacerbate psychosis. Other psychiatric reactions have also been reported, including acute toxic psychosis, agitation, speech disorder, hallucinations, paranoia, and delusions . Monitor patients for new or worsening psychiatric symptoms during treatment with scopolamine transdermal system. Also, monitor patients for new or worsening psychiatric symptoms during concomitant treatment with other drugs that are associated with similar psychiatric effects . In cases of psychiatric reactions occurring scopolamine transdermal system should be removed at once. If, despite this, the symptoms persist in a severe form, instruct patients to seek medical attention.

Seizures

Seizures and seizure-like activity have been reported in patients receiving scopolamine. …

Scopolamine Transdermal side effects

The following serious adverse reactions are described elsewhere in labeling:

•Acute Angle Closure Glaucoma

•Neuropsychiatric Adverse Reactions

•Eclamptic Seizures in Pregnant Women

•Gastrointestinal and Urinary Disorders

•Hyperthermia

•Drug Withdrawal/Post-Removal Symptoms

•Blurred Vision

•MRI Skin Burns

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Motion Sickness

The most common adverse reaction (approximately two thirds) was dry mouth. Less common adverse reactions, included drowsiness (less than one sixth), blurred vision and dilation of the pupils.

PONV

Common adverse reactions, occurring in at least 3% of patients in PONV clinical trials are shown in Table 1.

Table 1 Common Adverse Reactions* in Surgical Patients for the Prevention of PONV

Scopolamine Transdermal System

% (N = 461) | Placebo

% (N = 457)

Dry mouth | 29 | 16

Dizziness | 12 | 7

Somnolence | 8 | 4

Agitation | 6 | 4

Visual Impairment | 5 | 3

Confusion | 4 | 3

Mydriasis | 4 | 0

Pharyngitis | 3 | 2

*occurring in at least 3% of patients and at a rate higher than placebo

The following adverse reactions have been identified during post-approval use of scopolamine transdermal system. …

Drug interactions

The concurrent use of scopolamine transdermal system with other drugs that cause CNS adverse reactions of drowsiness, dizziness or disorientation (e.g., sedatives, hypnotics, opiates, anxiolytics and alcohol) or have anticholinergic properties (e.g., other belladonna alkaloids, sedating antihistamines, meclizine, tricyclic antidepressants, and muscle relaxants) may potentiate the effects of scopolamine transdermal system . Either scopolamine transdermal system or the interacting drug should be chosen, depending on the importance of the drug to the patient. If the interacting drug cannot be avoided, monitor patients for CNS adverse reactions.

Concomitant use of scopolamine with other drugs having anticholinergic properties may increase the risk of CNS adverse reactions , intestinal obstruction and/or urinary retention. Consider more frequent monitoring during treatment with scopolamine transdermal system in patients receiving anticholinergic drugs .

Scopolamine transdermal system, as an anticholinergic, may delay gastric and upper gastrointestinal motility and, therefore, the rate of absorption of other orally administered drugs. Monitor patients for modified therapeutic effect of concomitant orally administered drugs with a narrow therapeutic index. …

About this medicine

Scopolamine transdermal system is designed for continuous release of scopolamine following application to an area of intact skin on the head, behind the ear. Each system contains 1.3 mg of scopolamine base. Scopolamine is (9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl) 3-hydroxy-2-phenylpropanoate. The empirical formula is C17H21NO4 and its structural formula is:

Scopolamine has a molecular weight of 303.35 and a pKa of 7.55-7.81. The scopolamine transdermal system is a circular, 0.2 mm thick, 2.5 cm2 film with four layers. Proceeding from the visible surface towards the surface attached to the skin, these layers are: (1) a backing membrane of tan-colored, aluminized, polyester film; (2) a drug layer of scopolamine, crospovidone, isopropyl palmitate, light mineral oil, and polyisobutylene; (3) an ethylene vinyl acetate copolymer membrane that controls the rate of delivery of scopolamine from the system to the skin surface; and (4) a contact layer formulation of crospovidone, isopropyl palmitate, light mineral oil, polyisobutylene, and scopolamine. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID cb93bfad-3e37-4a27-92f6-f21703ae7bdf. Read the full official label on DailyMed.

Related medicines

Gabapentin Meloxicam Acetaminophen and Hydrocodone Duloxetine Prednisone Ibuprofen Tramadol Cyclobenzaprine